Related Experiment Video

Updated: Jun 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The inhibitory effect of statins on urinary 11-dehydrothromboxane levels

S Alusik1, Z Paluch, M Lejsková

  • 1Department of Medicine I, Thomayer University Hospital, Prague, Czech Republic. stefan.alusik@ftn.cz

International Angiology : a Journal of the International Union of Angiology
|May 27, 2010
PubMed

Insights

Three-month statin therapy significantly reduces urinary 11-dehydrothromboxane levels, a marker for cardiovascular risk, even when combined with acetylsalicylic acid. This therapy also lowers LDL cholesterol and C-reactive protein.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Elevated urinary 11-dehydrothromboxane indicates increased cardiovascular event risk.
  • Statins are known to inhibit platelet activity.
  • Acetylsalicylic acid is a common antiplatelet therapy.

Purpose of the Study:

  • To evaluate the impact of 3-month statin therapy on 11-dehydrothromboxane elimination.
  • To compare these effects in patients with and without concurrent acetylsalicylic acid therapy.

Main Methods:

  • 58 patients received 3-month statin therapy (simvastatin, fluvastatin, or atorvastatin).
  • Urinary 11-dehydrothromboxane levels were measured pre- and post-therapy.
  • Plasma lipid profiles, C-reactive protein, and blood glucose were also assessed.

Main Results:

  • Both patient groups (with and without acetylsalicylic acid) showed significant reductions in urinary 11-dehydrothromboxane.
  • Significant decreases in LDL cholesterol, total cholesterol, and C-reactive protein were observed.
  • No significant changes were noted in other measured parameters.

Conclusions:

  • Three-month statin therapy effectively reduces 11-dehydrothromboxane elimination, irrespective of acetylsalicylic acid use.
  • Statins offer additional benefits by lowering C-reactive protein levels.
  • Combination therapy with statins and acetylsalicylic acid may enhance outcomes in patients with suboptimal thromboxane inhibition.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...